If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

8th April, 2023

CAAT psychometric validation manuscript published

Home > News > CAAT psychometric validation manuscript published

We are pleased to announce that ‘Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD’ has been published in Respiratory Research.

The article reports psychometric validation of the Chronic Airways Assessment Test (CAAT), using baseline data from patients with a physician-assigned diagnosis of asthma and/or COPD in NOVELTY. The CAAT is a short eight-item patient-reported tool modified from the COPD Assessment Test (CAT) to assess health status in patients with asthma and/or COPD.

The CAAT showed good cross-sectional psychometric properties. The CAAT items were internally consistent within each diagnostic group, and models for structural and measurement invariance were strong. Although small differences were observed in individual items between asthma and COPD, these were not consistent in direction and had minimal overall impact on CAAT total score. Furthermore, the CAAT and CAT were highly consistent when assessed in the same patients.

In this study, CAAT total scores appeared to reflect the same health impairment in patients with asthma and COPD, indicating that the CAAT may be a suitable patient-reported outcome for assessing health status in patients with obstructive lung disease. The CAAT may be particularly relevant for use in routine clinical practice and clinical studies due to its brevity.

The full article is available here.

Read a summary of this article, and other NOVELTY publications and presentations here.


You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study